present updat model pharma
gi
simplif corpor structur simplifi
live corpor action big area focu us pharma
kept us busi recent month other wonder
effect bristol-my manag team abl
integr compani celgen size assum deal close
compani simplifi busi eli lilli recent
complet elanco exchang offer focus exclus human
health care addit ironwood close complet separ
new ironwood commerci stage gi-focus compani
investor react favor move note present
updat model lilli ironwood account
separ maintain neutral rate stock increas
target price
lilli diversifi growth stori attract valuat appear
reflect follow lli stock one top perform
pharma past year new product stori deliv
 commerci success given latest run stock howev
struggl find lever upsid time import upcom
data product tanezumab pegilodecakin could
prove us wrong allow share price appreci howev
somewhat cautiou olumi least us given recent
safeti data xeljanz verzenio least near-term
given sign satur see class
gi-focu make sens new ironwood asset need
deliv linzess obvious driver ironwood stori
still see reason growth ahead product could
catalyz new manag team posit phase
data addit abdomin symptom data expect
howev signific upsid like tie linaclotid
delay releas abdomin pain persist gerd
abl drive next chapter growth compani rare
diseas pipelin spend associ separ
new ironwood two program somewhat optimist
phase data product expect
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
updat model pharma
increas tp maintain neutral rate
bottom line complet split elanco updat
forecast account pharma busi beyond
model non-gaap ep repres accret
prior non-gaap ep includ full-year elanco
revis non-gaap ep
respect given latest run stock howev struggl find
lever upsid time maintain neutral rate import
upcom data product tanezumab pegilodecakin
could prove us wrong allow share price appreci
also watch potenti downsid risk estim trulic taltz
verzenio olumi
non-gaap ep guidanc assum split-off januari lilli
provid non-gaap pharma ep guidanc ep
call facilit understand y/i comp lilli indic
non-gaap ep assum lilly/elanco share exchang
began januari non-gaap ep pharma would
feel full impact share reduct exchang offer
contribut elanco entireti share count
vs prior guidanc non-gaap ep
base assumpt lilli includ elanco make
adjust amount time held anim health busi
ep calcul
increas target price new target price previous
blend dcf rel valuat
dcf appli wacc termin growth rate rel
valuat appli ep risk number includ
data pipelin
valuat metric
number share
price month
 close
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
blue sky valuat base greater sale
trulic jardianc taltz emgal olumi verzenio
compar current base case assumpt also model higher
gross margin oper margin base case
assumpt blue sky valuat base dcf driven
wacc growth termin rate
grey sky valuat base lower sale trulic
jardianc taltz emgal olumi verzenio compar
current base case assumpt grey sky valuat base
dcf driven wacc growth termin rate
price rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
figur stand-alone pharma ex-elanco guidanc given earn call
us million except per share data
figur impli pharma ep base midpoint pharma guidanc
us million unless otherwis state
sale
total incom expens
provis incom tax
compani data credit suiss estim beyond forecast pharma busi cs adjust estim base lilli restat year exclud elanco anim
need deliv increas tp
gi-focu make sens new ironwood asset need
deliv linzess obvious driver ironwood stori
still see reason growth ahead product need md-
persist gerd drive next chapter growth upsid
compani rare diseas pipelin spend associ
separ compani april
abdomin pain
notabl model updat multipl call compani gi
expert remov rare diseas pipelin model increas
estim persist gerd lower
normal sale astella collabor linaclotid base
compani guidanc earn call also significantli lower
oper expens new ironwood go forward given to-be-
separ pipelin account spend
accord pro-forma restat new ironwood statement
maintain neutral rate increas target price target
price base dcf valuat new ironwood cash flow
forecast use wacc termin
declin chang ep estim
respect main risk view
better/worse-than-expect growth linzess better/wors data
pipelin along chang expect investor may valu
upcom separ
valuat metric
number share
price month
 close
ironwood specialti pharmaceut compani involv
develop commerci drug gastrointestin condit
develop intern extern access
price rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base higher linzess
peak sale base case along higher probabl
success sale forecast pipelin asset md-
blue sky valuat base dcf driven
wacc along termin growth rate
grey sky valuat base lower
linzess peak sale base case sale pipelin
asset grey sky valuat base
dcf driven wacc along termin growth
 close
us thousand unless otherwis state
us million unless otherwis state
us thousand unless otherwis state
write-dow inventori net realiz valu loss non-cancel purchas commit
research develop
sell gener administr
amort acquir intang asset
loss fair valu remeasur cont consider
profit/ loss deriv
total expens net
profit loss tax
weight average share calcul dilut ep
compani mention price
